Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

66.03 USD -0.86 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 396,238
Open 66.91
Bid (Size) 66.03 (31)
Ask (Size) 66.05 (3)
Prev. Close 66.89
Today's Range 64.90 - 66.91
52wk Range 55.57 - 93.66
Shares Outstanding 104,259,256
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases 
From Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia 
From Business Wire News Releases

Performance

YTD
-11.76%
-11.76%
1 Month
+2.07%
+2.07%
3 Month
-1.03%
-1.03%
6 Month
-11.37%
-11.37%
1 Year
+12.14%
+12.14%

More News

Read More
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
From Business Wire News Releases
Arrowhead Earns $10 Million Phase 1 Milestone Payment
From Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
From Business Wire News Releases
Add Up The Pieces: RFG Could Be Worth $265
Tags ETFs
From ETF Channel
This investor crushes his fund’s benchmark with these 10 stocks
Tags ISRG TSLA GH
From MarketWatch
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
From Business Wire News Releases
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
From Business Wire News Releases
Notable Friday Option Activity: DDS, PLAN, ARWR
Tags Stocks
From Market News Video
Here's Why Inhibrx Stock Is on the Move Today
Tags DRNA VRTX Market News
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.